Attributes | Values |
---|
rdf:type
| |
Description
| - Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow
- Novel targeted drugs for the treatment of multiple myeloma (MM) are needed to improve outcome of MM patients. Bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge MA), a dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity in the 20S core of the 26S mammalian proteasome, is the first proteasome inhibitor that was approved by the US Food amd Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) for patients with relapsed and refractory MM who had received at least one prior therapy and who had already undergone or are unsuitable for the transplantation of bone marrow (en)
|
Title
| - Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma
- Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma (en)
|
skos:prefLabel
| - Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma
- Proteasome inhibition as a therapeutic strategy in patients with multiple myeloma (en)
|
skos:notation
| - RIV/00023736:_____/09:00008561!RIV10-MZ0-00023736
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(LC06044), Z(MZ0UHKT2005)
|
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023736:_____/09:00008561
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - multiple myeloma; proteasome; proteasome inhibitor bortezomib; apoptosis (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/mistoVydani
| |
http://linked.open...i/riv/nazevZdroje
| - Multiple myeloma : symptoms, diagnosis and treatment
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...v/pocetStranKnihy
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...n/vavai/riv/zamer
| |
number of pages
| |
http://purl.org/ne...btex#hasPublisher
| |
https://schema.org/isbn
| |